Ryaltris: Your combination to offer patients relief from the symptoms of Allergic Rhinitis - Fast 1-4

*NEW fixed dose combination of mometasone furoate and olopatadine hydrochloride indicated for symptomatic treatment of seasonal or perennial allergic rhinitis and associated ocular symptoms in adults and children of 6 years and older.

Provides greater relief from allergic rhinitis symptoms than its monocomponents

Fast onset of action

Provides relief from ocular symptoms of allergic rhinitis

Well tolerated and in a familiar plastic bottle

i TNSS: p,0.05 vs placebo. §0.52 change in average rTOSS va placebo(p<0.001).     ‡Low rates of adverse events up to 52 weeks.     1. Ryaltris Approved Product Information.     2. Gross GN et al. Ann Allergy Asthma Immunol 2019;122:630-638.     3. Hampel FC et al. Allergy Asthma Proc 2019;40(4):261-272.     4. Segall N et al. Allergy Asthma Proc 2019;40(5):301-310.     iTNSS: instantaneous Total Nasal Symptom Score     rTNSS: reflective total nasal symptom score.     rTOSS: reflective total ocular symptom score.